Sen. Lankford Keeps the Pressure on FTC to Investigate Drug-price Middlemen Practices Keeping Drug Costs High
June 16, 2022
June 16, 2022
WASHINGTON, June 16 -- Sen. James Lankford, R-Oklahoma, issued the following news release and letter on June 15, 2022:
Senator James Lankford (R-OK), a member of the Senate Finance Committee with jurisdiction over the Centers for Medicare and Medicaid Services (CMS), today sent a letter to Federal Trade Commission (FTC) Chair Lina Khan to encourage their ongoing investigation into the practices of drug-pricing middlemen known as Pharmacy Benefit Managers (PBMs), whose price-hike gim . . .
Senator James Lankford (R-OK), a member of the Senate Finance Committee with jurisdiction over the Centers for Medicare and Medicaid Services (CMS), today sent a letter to Federal Trade Commission (FTC) Chair Lina Khan to encourage their ongoing investigation into the practices of drug-pricing middlemen known as Pharmacy Benefit Managers (PBMs), whose price-hike gim . . .